Clinical trial
Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration.
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 946 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration
Actual Study Start Date: June 25, 2015
Actual Primary Completion Date: April 12, 2018
Estimated Study Completion Date: May 31, 2019
Arm:
- Experimental: abicipar pegol 2 mg (group A)
- Experimental: abicipar pegol 2 mg (group B)
- Active Comparator: ranibizumab
| Category | Value |
|---|---|
| Date last updated at source | 2018-05-01 |
| Study type(s) | Interventional |
| Expected enrolment | 946 |
| Study start date | 2015-06-25 |
| Estimated primary completion date | 2018-04-12 |